AU2004222137A1 - 2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound - Google Patents

2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound Download PDF

Info

Publication number
AU2004222137A1
AU2004222137A1 AU2004222137A AU2004222137A AU2004222137A1 AU 2004222137 A1 AU2004222137 A1 AU 2004222137A1 AU 2004222137 A AU2004222137 A AU 2004222137A AU 2004222137 A AU2004222137 A AU 2004222137A AU 2004222137 A1 AU2004222137 A1 AU 2004222137A1
Authority
AU
Australia
Prior art keywords
sulfonylamino
methoxypyridin
butyl
propyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004222137A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Goegelein
Gert Ulrich Kuerzel
Klaus Wirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2004222137A1 publication Critical patent/AU2004222137A1/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request for Assignment Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2004222137A 2003-03-18 2004-03-05 2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound Abandoned AU2004222137A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
DE10312073.4 2003-03-18
PCT/EP2004/002247 WO2004083157A1 (de) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, dessen verwendung als medikament sowie dieses enthaltende pharmazeutische zubereitungen

Publications (1)

Publication Number Publication Date
AU2004222137A1 true AU2004222137A1 (en) 2004-09-30

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004222137A Abandoned AU2004222137A1 (en) 2003-03-18 2004-03-05 2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound

Country Status (21)

Country Link
EP (1) EP1606237A1 (https=)
JP (1) JP2006520343A (https=)
KR (1) KR20050110681A (https=)
CN (1) CN100361943C (https=)
AR (1) AR043622A1 (https=)
AU (1) AU2004222137A1 (https=)
BR (1) BRPI0408441A (https=)
CA (1) CA2519022A1 (https=)
DE (1) DE10312073A1 (https=)
HR (1) HRP20050815A2 (https=)
MA (1) MA27749A1 (https=)
MX (1) MXPA05009763A (https=)
MY (1) MY176510A (https=)
NO (1) NO20054472L (https=)
NZ (1) NZ542476A (https=)
PE (1) PE20050307A1 (https=)
RS (1) RS20050690A (https=)
RU (1) RU2333202C2 (https=)
TW (1) TW200500342A (https=)
WO (1) WO2004083157A1 (https=)
ZA (1) ZA200506328B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007015775A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
EP2435407B1 (en) * 2009-05-29 2019-12-25 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053B1 (en) * 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
PE20050307A1 (es) 2005-06-08
DE10312073A1 (de) 2004-09-30
TW200500342A (en) 2005-01-01
HK1086819A1 (en) 2006-09-29
RU2005132163A (ru) 2006-04-10
RS20050690A (sr) 2008-04-04
MY176510A (en) 2020-08-12
WO2004083157A1 (de) 2004-09-30
RU2333202C2 (ru) 2008-09-10
ZA200506328B (en) 2006-04-26
MA27749A1 (fr) 2006-02-01
MXPA05009763A (es) 2006-01-27
CN100361943C (zh) 2008-01-16
BRPI0408441A (pt) 2006-04-04
JP2006520343A (ja) 2006-09-07
NZ542476A (en) 2008-05-30
CN1756728A (zh) 2006-04-05
KR20050110681A (ko) 2005-11-23
AR043622A1 (es) 2005-08-03
NO20054472L (no) 2005-09-27
CA2519022A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
EP1606237A1 (de) 2005-12-21

Similar Documents

Publication Publication Date Title
EP1385820B1 (de) Anthranilsäureamide, verfahren zu ihrer herstellung, ihre verwendung als antiarrhythmika sowie pharmazeutische zubereitungen davon
JP4445198B2 (ja) カリウムチャンネルインヒビターとして使用するためのオルソ置換含窒素ビスアリール化合物
JP4051283B2 (ja) オルト−置換およびメタ−置換ビスアリール化合物、その製造法、医薬としてのその使用、並びにそれを含有する医薬製剤
EP0920438B1 (en) N6 heterocyclic substituted adenosine derivatives
KR20040030668A (ko) 헤테로아릴설포닐 측쇄를 갖는 안트라닐산 아미드, 이의제조방법, 약제 또는 진단제로서의 이의 용도 및 당해화합물을 함유하는 약제학적 제제
MX2011012559A (es) Moduladores de lxr.
US20020193422A1 (en) Anthranilamides and methods of their use
AU2004222137A1 (en) 2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
JP7032323B2 (ja) Ｎ－ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体
US8106099B2 (en) Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
JP4658919B2 (ja) フェニルカルボン酸アミドおよびＩＫｒチャンネル遮断剤の組み合わせならびに心房性不整脈を処置するためのその使用
US20080081926A1 (en) Sulfonylaminobenzoic acid and salt
US20050054673A1 (en) Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
AU2004271697A1 (en) Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias
HK1086819B (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]- benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
JP2003503478A (ja) 神経学的疾患の治療のためのβ−アミノ酸誘導体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application